23 июл. 2024 г. · Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make ...

The cost for Sunlenca 300 mg oral tablet is around $3,432 for a supply of 4 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying ...

22 дек. 2022 г. · Sunlenca injection and tablets are expected to cost $42,250 in the first year of therapy and $39,000 annually after that, the company told ...

26 авг. 2024 г. · Sunlenca's list price is $42,250 a year. In comparison, Gilead also manufactures Descovy, the leading brand name oral PrEP medication, which ...

Sunlenca (lenacapavir) is a capsid antiviral inhibitor indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adult patients.

12 янв. 2023 г. · Gilead confirmed that Sunlenca injection and tablets are expected to cost $42,250 in the first year of therapy and $39,000 annually after ...

13 сент. 2024 г. · ... Sunlenca, lenacapavir as treatment for HIV infection is pricey, costing $3450 per month or over $41,000 per year, NBC News reported. Its price ...

27 авг. 2024 г. · The drug is sold under the brand name Sunlenca, which Gilead launched with a list price of $42,250 per year. To put the Sunlenca price tag in ...

11 сент. 2023 г. · In the US, during the initial year of therapy, the wholesale acquisition cost (WAC) for Sunlenca injections and tablets is $42,250 per year.

24 июл. 2024 г. · ... Sunlenca could cost as little as $40 a year per patient, a whopping thousand times less than its current price of over $42,000, The Guardian ...